phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»10.37489/2587-7836-2020-4-3-8phkinetica-260Research ArticleОБЗОРЫREVIEWSФармакокинетические закономерности в проявлении действия психотропных лекарственных средствPharmacokinetic relationships in psychotropic drugs effectshttps://orcid.org/0000-0002-2571-0047КолывановГ. Б.KolyvanovG. B.

Колыванов Геннадий Борисович – доктор биологических наук, ведущий научный сотрудник лаборатории фармакокинетики

Москва

SPIN-код: 2538-8639

Kolyvanov Gennadiy B. – D. Sci. in Biology, Leading researcher of the laboratory of pharmacokinetics

Moscow

SPIN code: 2538-8639

https://orcid.org/0000-0002-2818-3457ЛитвинА. А.LitvinA. A.

Литвин Александр Алексеевич – доктор биологических наук, ведущий научный сотрудник лаборатории фармакокинетики

Москва

SPIN-код: 6193-5770

Litvin Alexander A. – D. Sci. in Biology, Leading researcher of the laboratory of pharmacokinetics

Moscow

SPIN code: 6193-5770

litbiopharm@yandex.ruhttps://orcid.org/0000-0003-4646-7733ШевченкоР. В.ShevchenkoR. V.

Шевченко Роман Владимирович – кандидат медицинских наук, научный сотрудник лаборатории фармакокинетики

Москва

SPIN-код: 1844-6202

Shevchenko Roman V. – PhD in Medicine, Research Officer of laboratory pharmacokinetics

Moscow

SPIN code: 1844-6202

https://orcid.org/0000-0002-6152-4778РаскинС. Ю.RaskinS. Yu.

Раскин Сергей Юрьевич – кандидат медицинских наук, научный сотрудник лаборатории фармакокинетики

Москва

SPIN-код: 5234-7871

Raskin Sergey Yu. – PhD in Medicine, Research Officer of laboratory pharmacokinetics

Moscow

SPIN code: 5234-7871

https://orcid.org/0000-0001-8555-5969БочковП. О.BochkovP. O.

Бочков Павел Олегович кандидат биологических наук, старший научный сотрудник лаборатории фармакокинетики

Москва

SPIN-код: 5576-8174

Bochkov Pavel O. – PhD in Biology, Senior Research Officer of laboratory pharmacokinetics

Moscow

SPIN code: 5576-8174

https://orcid.org/0000-0003-2710-7134ЖердевВ. П.ZherdevV. P.

Жердев Вдадимир Павлович доктор медицинских наук, профессор, заведующий лабораторией фармакокинетики

Москва

SPIN-код: 2213-9592

Zherdev Vladimir P. – D. Sci. in Medicine, Professor, Head of laboratory pharmacokinetics

Moscow

SPIN-код: 2213-9592

ФГБНУ «НИИ фармакологии имени В.В. Закусова»РоссияFSBI «Zakusov Institute of Pharmacology»Russian Federation2020240620210438Copyright © Колыванов Г.Б., Литвин А.А., Шевченко Р.В., Раскин С.Ю., Бочков П.О., Жердев В.П., 20212021Колыванов Г.Б., Литвин А.А., Шевченко Р.В., Раскин С.Ю., Бочков П.О., Жердев В.П.Kolyvanov G.B., Litvin A.A., Shevchenko R.V., Raskin S.Y., Bochkov P.O., Zherdev V.P.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/260

В обзоре обсуждаются взаимосвязи между фармакокинетическими показателями и эффектами психотропных лекарственных средств как в доклинических исследованиях, так и в клинической практике. Выявление таких корреляций может служить основой для понимания сложной системы взаимоотношений фармакокинетических и фармакодинамических механизмов в проявлении действия этой группы препаратов и позволяет использовать данные фармакокинетических исследований для оптимизации терапевтических подходов в лечебной практике.

The review discusses relationships between pharmacokinetic parameters and effects of psychotropic drugs, both in preclinical studies and clinical practice. The identification of such correlations can serve as a basis for understanding the complex system of relationships between pharmacokinetic and pharmacodynamic mechanisms in the manifestation of the action of this group of drugs and allows us to use the data of pharmacokinetic studies to optimize therapeutic approaches in medical practice.

психотропные препаратыфармакокинетикафармакодинамикакорреляцияpsychotropic drugspharmacokineticspharmacodynamicscorrelationReferencesGabrielsson JL, Weiner DL. Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm Sci Technol Today. 1999 Jun;2(6): 244–252. DOI:10.1016/s1461-5347(99)00162-5.Gabrielsson JL, Weiner DL. Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm Sci Technol Today. 1999 Jun;2(6): 244–252. DOI:10.1016/s1461-5347(99)00162-5.Jann MW, Penzak SR, Cohen LJ. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. New York: Springer; 2016.Jann MW, Penzak SR, Cohen LJ. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. New York: Springer; 2016.Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 4th ed., New York: Wolters Kluwer Health/Lippincott William & Wilkins; 2011.Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications, 4th ed., New York: Wolters Kluwer Health/Lippincott William & Wilkins; 2011.Жердев В.П., Бойко С.С., Константинопольский М.А. и др. Фармакокинетика и фармакодинамика фармацевтических композиций дипептидного анксиолитика ГБ-115 // Химико-фармацевтический журнал. – 2016. – Т. 50. – № 5. – С. 42–46. OI:10.30906/0023-1134-2016-50-5-42-46.Zherdev VP, Boyko SS, Konstantinopolskiy MA et al. Preclinical study of dipeptide anxiolytic GB-115 pharmaceutical compositions: pharmacokinetics and pharmacodynamics. Khimiko-farmacevticheskiy zhurnal. 2016;50(5):42–46. (In Russ). DOI:10.30906/0023-1134-2016-50-5-42-46.Фирсов А.А., Жердев В.П., Портной Ю.А. и др. Руководство по проведению доклинических исследований лекарственных средств / Под ред. А. Н. Миронова. Часть 1, – М.: «Гриф и К»; 2013. – С. 845–855.Firsov AA, Zherdev VP, Portnoy YuA et al. Rukovodstvo po provedeniyu doklicheskikh issledovaniyi lekarstvennykh sredtsv. Part one. Ed. By Mironov AN. Moscow: Grif i K; 2013. (In Russ).Середенин С.Б., Воронина Т.А., Незнамов Г.Г., Жердев В.П. Феназепам: 25 лет в медицинской практике. – М.: Наука; 2007. – 381 с.Seredenin SB, Voronina TA, Neznamov GG, Zhardev VP. Fenazepam: 25 let v medicinskoy praktike. Moscow: Nauka; 2007. (In Russ).Briley M, Nutt DJ, editors. Anxiolytics. B.: Birkhäuser; 2000.Briley M, Nutt DJ, editors. Anxiolytics. B.: Birkhäuser; 2000.Mandema JW, Kuck MT, Danhof M. Differences in intrinsic efficacy of benzodiazepines are reflectedin their concentration-EEG effect relationship. Br J Pharmacol. 1992;105(1):164–170. DOI: 10.1111/j.1476-5381.1992.tb14229.x.Mandema JW, Kuck MT, Danhof M. Differences in intrinsic efficacy of benzodiazepines are reflectedin their concentration-EEG effect relationship. Br J Pharmacol. 1992;105(1):164–170. DOI: 10.1111/j.1476-5381.1992.tb14229.x.Яркова М.А., Литвин А.А., Колыванов Г.Б. и др. Поиск взаимосвязи между анксиолитическим действием оригинального производного пирроло[1,2-a]пиразина, лиганда TSPO – ГМЛ-1 и его концентрациями в плазме крови крыс // Фармакокинетика и фармакодинамика. – 2018. – № 2. – С. 52–58. DOI: 10.24411/2587-7836-2018-10014.Yarkova MA, Litvin AA et al. Search of the correlation between anxiolytic effect of original derivative of pyrrolo[1,2-a]pyrazine TSPO-ligand (GML-1) and its concentrations in the rat blood plasma. Farmakokinetika i farmakodinamika. 2018;(2):52–58. (In Russ). DOI: 10.24411/2587-7836-2018-10014.Bialer M, Twyman RE, White HS. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy & Behavior. 2004;5(6):866–872. DOI:10.1016/j.yebeh.2004.08.021.Bialer M, Twyman RE, White HS. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy & Behavior. 2004;5(6):866–872. DOI:10.1016/j.yebeh.2004.08.021.Vuu I, Coles LD, Maglalang P et al. Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy. Frontiers in Veterinary Science. 2016;3(107):1–8. DOI: 10.3389/fvets.2016.00107.Vuu I, Coles LD, Maglalang P et al. Intravenous Topiramate: Pharmacokinetics in Dogs with Naturally Occurring Epilepsy. Frontiers in Veterinary Science. 2016;3(107):1–8. DOI: 10.3389/fvets.2016.00107.Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14(3):245-50. DOI:10.1016/j.euroneuro.2003.09.001.Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14(3):245-50. DOI:10.1016/j.euroneuro.2003.09.001.Müller MJ, Eich F, Regenbogen B et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol. 2009;23(3):278–286. DOI: 10.1177/0269881108089806.Müller MJ, Eich F, Regenbogen B et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol. 2009;23(3):278–286. DOI: 10.1177/0269881108089806.Müller MJ, Regenbogen B, Sachse J et al. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry. 2006;39(2):41–46. DOI: 10.1055/s-2006-931540.Müller MJ, Regenbogen B, Sachse J et al. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study. Pharmacopsychiatry. 2006;39(2):41–46. DOI: 10.1055/s-2006-931540.Müller MJ, Regenbogen B, Härtter S et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res. 2007;41(8):673–679. DOI: 10.1016/j.jpsychires.2005.10.003.Müller MJ, Regenbogen B, Härtter S et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res. 2007;41(8):673–679. DOI: 10.1016/j.jpsychires.2005.10.003.Haring C, Fleischhacker WW, Schett P et al. Influence of patientrelated variables on clozapine plasma levels. Am J Psychiatry. 1990;147(11):1471–1475. DOI: 10.1176/ajp.147.11.1471.Haring C, Fleischhacker WW, Schett P et al. Influence of patientrelated variables on clozapine plasma levels. Am J Psychiatry. 1990;147(11):1471–1475. DOI: 10.1176/ajp.147.11.1471.Haring C, Meise U, Humpel C et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology. 1989;99 Suppl:S38-40. DOI: 10.1007/BF00442557.Haring C, Meise U, Humpel C et al. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology. 1989;99 Suppl:S38-40. DOI: 10.1007/BF00442557.Ng CH, Chong SA, Lambert T et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20(3):163–168. DOI: 10.1097/00004850-200505000-00007.Ng CH, Chong SA, Lambert T et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol. 2005;20(3):163–168. DOI: 10.1097/00004850-200505000-00007.Xiang YQ, Zhang ZJ, Weng YZ et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophrenia Research. 2006;83(2-3):201–210. DOI: 10.1016/j.schres.2006.01.011.Xiang YQ, Zhang ZJ, Weng YZ et al. Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schizophrenia Research. 2006;83(2-3):201–210. DOI: 10.1016/j.schres.2006.01.011.Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract. 2005;11(5):289-–301. DOI: 10.1097/00131746-200509000-00003.Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiatr Pract. 2005;11(5):289-–301. DOI: 10.1097/00131746-200509000-00003.Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol. 2003;17(2):234–238. DOI: 10.1177/0269881103017002014.Greenwood-Smith C, Lubman DI, Castle DJ. Serum clozapine levels: a review of their clinical utility. J Psychopharmacol. 2003;17(2):234–238. DOI: 10.1177/0269881103017002014.Yusufi B, Mukherjee S, Flanagan R et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol. 2007;22(4):238–243. DOI: 10.1097/YIC.0b013e32819f8f17.Yusufi B, Mukherjee S, Flanagan R et al. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol. 2007;22(4):238–243. DOI: 10.1097/YIC.0b013e32819f8f17.Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by highperformance liquid chromatography with electrochemical detection Ther Drug Monit. 1997;19(3):307-313. DOI: 10.1097/00007691-199706000-00011.Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by highperformance liquid chromatography with electrochemical detection Ther Drug Monit. 1997;19(3):307-313. DOI: 10.1097/00007691-199706000-00011.Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull. 2001;35(3):19-29.Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull. 2001;35(3):19-29.Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37(2): 63–68. DOI: 10.1055/s-2004-815527.Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37(2): 63–68. DOI: 10.1055/s-2004-815527.Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25(1):46–53. DOI: 10.1097/00007691-200302000-00007.Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25(1):46–53. DOI: 10.1097/00007691-200302000-00007.Mauri MC, Steinhilber CP, Marino R et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. European Psychiatry. 2005;20(1):55–60. DOI: 10.1016/j.eurpsy.2004.09.009.Mauri MC, Steinhilber CP, Marino R et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. European Psychiatry. 2005;20(1):55–60. DOI: 10.1016/j.eurpsy.2004.09.009.Rao ML, Hiemke C, Grasmäder K, Baumann P. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr. 2001;69(12):580–582. DOI: 10.1055/s-2001-19184.Rao ML, Hiemke C, Grasmäder K, Baumann P. Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring. Fortschr Neurol Psychiatr. 2001;69(12):580–582. DOI: 10.1055/s-2001-19184.Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens — when does therapeutic become toxic? J Forensic Sci. 2000;45(2):418–421.Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens — when does therapeutic become toxic? J Forensic Sci. 2000;45(2):418–421.Dragicevic A, Müller MJ, Sachse J, Härtter S, Hiemke C. Therapeutic drug monitoring (TDM) of quetiapine. Pharmacopsychiatry. 2003;36(5):58. DOI:10.1097/00007691-200404000-00012.Dragicevic A, Müller MJ, Sachse J, Härtter S, Hiemke C. Therapeutic drug monitoring (TDM) of quetiapine. Pharmacopsychiatry. 2003;36(5):58. DOI:10.1097/00007691-200404000-00012.Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit. 2004;26(5): 486–491. DOI: 10.1097/00007691-200410000-00005.Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit. 2004;26(5): 486–491. DOI: 10.1097/00007691-200410000-00005.Aichhorn W, Marksteiner J, Walch T et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21(2):81–85. DOI: 10.1097/01.yic.0000188213.46667.f1.Aichhorn W, Marksteiner J, Walch T et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21(2):81–85. DOI: 10.1097/01.yic.0000188213.46667.f1.Mauri MC, Volonteri LS, Fiorentini A et al. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007;8(14):2207–2213. DOI: 10.1517/14656566.8.14.2207.Mauri MC, Volonteri LS, Fiorentini A et al. Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007;8(14):2207–2213. DOI: 10.1517/14656566.8.14.2207.Hiemke C, Dragicevic A, Gründer G et al. Therapeutic monitoring of new antipsychotic drug. Ther Drug Monit. 2004;26(2):156-160. DOI: 10.1097/00007691-200404000-00012.Hiemke C, Dragicevic A, Gründer G et al. Therapeutic monitoring of new antipsychotic drug. Ther Drug Monit. 2004;26(2):156-160. DOI: 10.1097/00007691-200404000-00012.Dragicevic A, Trotzauer D, Hiemke C, Müller MJ. Gender and age effects on quetiapine serum concentrations in patients with schizophrenia or schizoaffective disorders. Pharmacopsychiatry. 2005;38(5):44. DOI:10.1055/s-2003-38084.Dragicevic A, Trotzauer D, Hiemke C, Müller MJ. Gender and age effects on quetiapine serum concentrations in patients with schizophrenia or schizoaffective disorders. Pharmacopsychiatry. 2005;38(5):44. DOI:10.1055/s-2003-38084.Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22(1):49–68. DOI: 10.2165/00023210-200822010-00004.Sparshatt A, Jones S, Taylor D. Quetiapine: dose-response relationship in schizophrenia. CNS Drugs. 2008;22(1):49–68. DOI: 10.2165/00023210-200822010-00004.Olesen OV, Licht RW, Thomsen E et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20(4):380-384. DOI: 10.1097/00007691-199808000-00004.Olesen OV, Licht RW, Thomsen E et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20(4):380-384. DOI: 10.1097/00007691-199808000-00004.Remington G, Mamo D, Labelle A et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163(3):396-401. DOI: 10.1176/appi.ajp.163.3.396.Remington G, Mamo D, Labelle A et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006;163(3):396-401. DOI: 10.1176/appi.ajp.163.3.396.Lane HY, Chiu WC, Chou JC et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry. 2000;61(3):209-14. DOI: 10.4088/jcp.v61n0311.Lane HY, Chiu WC, Chou JC et al. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry. 2000;61(3):209-14. DOI: 10.4088/jcp.v61n0311.Nyberg S, Farde L, Halldin C et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152(2):173–178. DOI: 10.1176/ajp.152.2.173.Nyberg S, Farde L, Halldin C et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152(2):173–178. DOI: 10.1176/ajp.152.2.173.Taylor D. Risperidone long-acting injection in practice – more questions than answers? Acta Psychiatrica Scandinavica. 2006;114(1):1–2. DOI: 10.1111/j.1600-0447.2006.00810.x.Taylor D. Risperidone long-acting injection in practice – more questions than answers? Acta Psychiatrica Scandinavica. 2006;114(1):1–2. DOI: 10.1111/j.1600-0447.2006.00810.x.Gefvert O, Eriksson B, Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta TM) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8(1): 27–36. DOI: 10.1017/S1461145704004924.Gefvert O, Eriksson B, Persson P et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta TM) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8(1): 27–36. DOI: 10.1017/S1461145704004924.Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol. 2006;16(4):233–240. DOI: 10.1016/j.euroneuro.2005.10.006.Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol. 2006;16(4):233–240. DOI: 10.1016/j.euroneuro.2005.10.006.Joris C. Verster, Roth T. Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. Sleep Medicine Reviews. 2013;17(2):153–159. DOI: 10.1016/j.smrv.2012.05.004.Joris C. Verster, Roth T. Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. Sleep Medicine Reviews. 2013;17(2):153–159. DOI: 10.1016/j.smrv.2012.05.004.Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci. 2002;91(1):18–31. DOI: 10.1002/jps.1167.Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci. 2002;91(1):18–31. DOI: 10.1002/jps.1167.

The authors declare that there are no conflicts of interest present.